about
Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer.A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiationA novel method for generating and screening peptides and libraries displayed on adenovirus fiberAdenovirus targeting to prostate-specific membrane antigen through virus-displayed, semirandom peptide library screening.Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.A novel approach for detecting viable and tissue-specific circulating tumor cells through an adenovirus-based reporter vector.A real time Metridia luciferase based non-invasive reporter assay of mammalian cell viability and cytotoxicity via the β-actin promoter and enhancer.Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector.Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses.Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening.Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablationCryoimmunotherapy in urologic oncology.Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy.Characterization of a novel metastatic prostate cancer cell line of LNCaP origin.Bicalutamide-activated oncolytic adenovirus for the adjuvant therapy of high-risk prostate cancer.Mechanism of growth inhibition of prostate cancer xenografts by valproic acid.Does valproic acid induce neuroendocrine differentiation in prostate cancer?Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer.miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth.Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo.Androgen receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent adenoviruses.Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy.Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells.Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells.Evaluation of prostate-specific membrane antigen as an imaging reporter.XBSeq2: a fast and accurate quantification of differential expression and differential polyadenylation.Loss of Cyclin-Dependent Kinase Inhibitor Alters Oncolytic Adenovirus Replication and Promotes More Efficient Virus Production.1623 A FLUORESCENT IMAGING AGENT SPECIFICALLY TARGET PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CELLS308. Valproic Acid, a Histone Deacetylase Inhibitor, Is an Antagonist for Oncolytic Adenoviral Gene TherapyV1221 INTRAOPERATIVE USE OF A PROSTATE SPECIFIC MEMBRANE ANTIGEN-BASED FLUORESCENT IMAGING AGENT FOR PROSTATE CANCER IN A MOUSE MODEL
P50
Q27346788-2467EFE7-B0A5-4AD2-BE93-D6F7BCB37082Q28260029-38FB80A9-035A-4E70-AEFC-2CA7FF619872Q33304147-49A14821-7365-4C5F-941B-F8B72E432C0EQ33645206-7C9A3B03-1046-44F8-A00A-DCA50BB6660EQ33893647-E4A0EF63-309A-4CB6-8AF8-BD2493FDC214Q34036427-1B399944-DFE1-4145-BFBB-E8EBB662F1EBQ34270806-B46F648E-8A31-4AFA-9BE8-3486DD0235ADQ34591133-7BC06982-A20F-4043-B741-61DD755C4F2BQ34992785-527BE0EB-EBD8-4A8E-9A14-2EE2FFDDD39EQ36147506-155EC6DD-F7C4-433B-BE9B-C633F8CCB9CFQ37268005-42705B87-7E2C-496D-9E0C-A210148F25EBQ37598432-36A625E7-E382-4569-B2B9-372AA3BC5EF3Q37698968-2BE978B6-2F9A-4FB8-9A9A-23B133C9CC8CQ38825095-4EA16D0F-B9FA-4DD5-8F79-9D55F4DE8B93Q39139906-380BB0ED-628D-4955-9E54-C3CFA5DDA55FQ39254228-0F4A2E42-168A-4D62-BC5F-BEC624590823Q39638991-D513AA12-8CB0-4865-8C9E-3DFF16AE759BQ39732460-64D3AC0A-1823-4BF9-824B-A7B6F7A0F09EQ39802027-A113D21A-1B06-42FB-8363-40B2D89D5598Q39860046-FE964A91-C25D-4F87-9F34-DC4F1C3ACA16Q40120649-8043A3F0-E78C-4A45-99A7-F834227AB8F1Q40228873-DDF876B6-CBF9-405F-A52D-567EEB57E21EQ40251579-B55556EB-2232-45D3-A0DE-17203711FF7CQ40253999-7615EA4E-9988-4192-9E84-E7547A48D5BFQ40561027-A0BB3ACC-8DEE-4F00-91B0-0FAF771FEC39Q41462083-FA004608-59C1-4AD9-9B72-01DC44EC93ACQ42276805-FC5D81B7-7C24-4025-BC94-F33105AF50B2Q55515593-E297856D-4CBC-44DF-A900-75E49205C0E3Q57927912-A6C6EF20-10D7-4284-94BE-F692A1596858Q57927916-2833D156-B8AF-4A1D-9677-DF69ABBBCDE3Q57927927-D042C17A-4FA9-4CC4-81F9-927A0884722B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Wasim H Chowdhury
@es
Wasim H. Chowdhury
@en
Wasim H. Chowdhury
@nl
Wasim H. Chowdhury
@sl
type
label
Wasim H Chowdhury
@es
Wasim H. Chowdhury
@en
Wasim H. Chowdhury
@nl
Wasim H. Chowdhury
@sl
prefLabel
Wasim H Chowdhury
@es
Wasim H. Chowdhury
@en
Wasim H. Chowdhury
@nl
Wasim H. Chowdhury
@sl
P106
P1153
6506216297
P21
P31
P496
0000-0002-6731-646X
P569
2000-01-01T00:00:00Z